<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05161026</url>
  </required_header>
  <id_info>
    <org_study_id>19-047</org_study_id>
    <nct_id>NCT05161026</nct_id>
  </id_info>
  <brief_title>Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry</brief_title>
  <acronym>REMODALLO</acronym>
  <official_title>Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry Coupled With FRAX / TBS in Allo-HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs&#xD;
      transplant in hematologic malignancies. Comparison with the general population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allo-HSCTs performed for the treatment of hematologic malignancies has been increasing in&#xD;
      recent years. There is therefore a growing interest in the quality of life of these patients&#xD;
      and in particular for the bone complications of the transplant. Indeed, it was found a high&#xD;
      incidence of osteoporosis / osteopenia in this population associated with an increased risk&#xD;
      of osteoporotic fracture from 6 to 9 times compared to the general population.&#xD;
&#xD;
      This study will evaluate the variation of mineral density and bone microarchitecture&#xD;
      parameters by bone densitometry with measurement of trabecular bone score and fracturing risk&#xD;
      before and after allogeneic HSCTs transplant, at predefined times. It's also evaluating pain&#xD;
      scale, fracture incidence and bone remodeling markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density evaluation</measure>
    <time_frame>change over time between diagnostic, transplant, 6 months and 12 months post-transplant</time_frame>
    <description>bone mineral density evaluation post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone mineral density evaluation</measure>
    <time_frame>change over time between 24 months and 36 months post-transplant</time_frame>
    <description>long term bone mineral density evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone architectural abnormalities and fracture risk</measure>
    <time_frame>change over time between diagnostic, transplant, 6 months and 12 months post-transplant</time_frame>
    <description>evaluation of bone architectural abnormalities and fracture risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone remodeling markers</measure>
    <time_frame>change over time between diagnostic, transplant, 6 months and 12 months post-transplant</time_frame>
    <description>Dosage of bone remodeling markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation</measure>
    <time_frame>change over time between diagnostic, transplant, 6 months, 12 months, 24 months and 36 months post-transplant</time_frame>
    <description>Pain evaluation (EVA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Myeloid Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Patients with AML</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with AML</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone osteodensitometry</intervention_name>
    <description>Evaluation of bone osteodensitometry</description>
    <arm_group_label>Patients with AML</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line&#xD;
             allo-HSCTs transplant&#xD;
&#xD;
          -  Patient affiliated to the social security system&#xD;
&#xD;
          -  For women of childbearing age, use of reliable contraception throughout the study in&#xD;
             accordance with the CPR of the drugs used.&#xD;
&#xD;
          -  The patient must be able to comply with study visits and per protocol procedures&#xD;
&#xD;
          -  Patient who has been informed of the study and has signed his informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person under guardianship or curatorship, or unable to understand the purpose of the&#xD;
             study.&#xD;
&#xD;
          -  Hematologic malignancies other than AML&#xD;
&#xD;
          -  History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...)&#xD;
             and/or any solid cancer less than 5 years old&#xD;
&#xD;
          -  History of fracture of the femoral neck prior to the diagnosis of hematologic&#xD;
             malignancies&#xD;
&#xD;
          -  Known bone involvement related to AML at diagnosis&#xD;
&#xD;
          -  Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies&#xD;
&#xD;
          -  Corticotherapy &gt; 3 months at a dose &gt; 7.5mg/day prior to the diagnosis of&#xD;
             hematological disease&#xD;
&#xD;
          -  Autograft or anterior allograft&#xD;
&#xD;
          -  Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid&#xD;
             arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR &lt; or = at&#xD;
             30ml / min / 1.73m2)&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agathe FARGE, PhD</last_name>
    <phone>+33 2.31.27.21.40</phone>
    <email>farge-a@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DRCI secretary</last_name>
    <phone>+33.2.31.06.57.81</phone>
    <email>drci-sec@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MAROLLEAU Jean-Pierre, MD/PhD</last_name>
      <phone>+33 3.22.45.59.20</phone>
      <email>marolleau.jean-pierre@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Agathe FARGE, PhD</last_name>
      <phone>+33 2.31.27.21.40</phone>
      <email>farge-a@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle LEGROUX, PhD</last_name>
      <phone>+33 3.20.44.59.62</phone>
      <email>Isabelle.legroux@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice JARDIN, MD/PhD</last_name>
      <phone>+33 2.32.08.24.51</phone>
      <email>fabrice.jardin@rouen.fnclcc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allo-HSCTs transplant</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

